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Summary: Cathepsin D serum mass concentrations were determined by enzyme immunoassay in patients with
hepatocellular carcinoma (n = 51) and/or liver cirrhosis (n = 92) or benign steatosis (n = 16) and correlated with
some biochemical and clinical properties of these diseases. Increased cathepsin D serum mass concentrations
(P < 0.001) were observed in all these groups of patients as compared to normal subjects (n = 98). However,
patients with steatosis had serum mass concentrations of this enzyme significantly lower (mean 2—3 fold) than
those measured in cancer patients (P < 0.05) or cirrhotic patients (P < 0.001). Interestingly, significantly higher
cathepsin D serum mass concentrations (mean + 62%) (P < 0.006) were determined in the cirrhosis group as
compared to cancer patients. No correlation between cathepsin D and a number of clinical and biochemical proper-
ties examined, namely, α-foetoprotein, number of neoplastic lesions and tumour size in cancer patients or, Child-
Pugh grade of severity of cirrhosis and other enzymes of liver function tests in the cirrhotic group was found. The
present data and those from other studies which indicate that cathepsin D may be involved in carcinogenesis suggest
that this enzyme may be potentially useful as an additional biochemical marker to identify cirrhotic patients who
may develop precancerous hepatic nodules.
Introduction.
Cathepsin D1) is a lysosomal acidic endopeptidase
widely distributed in animal and human tissues (1). This
enzyme has been suggested to be mainly involved, in
physiological conditions, in intracellular protein catabol-
ism (1). However, growing experimental evidence indi-
cates that cathepsin D may also promote tumour pro-
gression, invasion and metastasis (2, 3). In fact several
investigations have shown that this proteinase appears
to facilitate, at least in vitro, oncogenic transformation
(4). Moreover, it has been shown that a number of hu-
man carcinoma cell lines actively secrete a precursor
form of cathepsin D which, following autoactivation at
an acid pH, may degrade extracellular matrix or may
activate latent precursor forms of other proteolytic en-
zymes involved in the metastatic cascade (2, 3). In addi-
tion, it has been recently shown that this precursor form
may be endowed with mitogenic activity, thus facilitat-
ing tumour cell proliferation (5, 6). Although evident
proof that cathepsin D may also facilitate these pro-
l) Enzymes
Cathepsin D (EC 3.4.23.5)
Alkaline phosphatase (EC 3.1.3.1)
Alanine aminotransferase (EC 2.6.1.2)
Aspartate aminotransferase (EC 2.6.1.1)
γ-Glutamyl-transferase (EC 2.3.2.2)
cesses in vivo has still not been provided, a consistent
bulk of clinical studies have shown that this enzyme is
highly expressed, in terms of mass and/or catalytic activ-
ity concentrations, in tumour cells and tissues of a
number of human neoplastic diseases as compared to
their normal counterpart and that these levels may corre-
late, in some cases, with the malignant progression of
these tumours (7—13). In this context several studies
have also shown increased cathepsin D catalytic activity
concentrations in human liver tumours as compared to
normal liver tissues (14) as well elevated plasma mass
concentrations of this enzyme in patients with malignant
and non-malignant liver diseases as compared to healthy
subjects (15). Interestingly, recent experimental in vitro
and in vivo studies (16, 17) have evidenced in rat hepa-
toma cells altered intracellular processing and increased
secretion of a precursor form of cathepsin D which ap-
pears to be endowed with mitogenic activity and a sig-
nificant increase of the catalytic activity concentration
of this enzyme in the ascites and in plasma of rats trans-
planted with Yoshida AH-130 hepatoma. An important
consequence related to these phenomena may be, as sug-
gested (14, 15, 18), that cathepsin D produced in excess
or unusually distributed at extracellular levels following
these pathological processes, may be actively secreted
into the bloodstream. Therefore, increased cathepsin D
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serum content may reflect the presence of neoplastic
nodules in liver tissue or may also be related to the ma-
lignant transformation of cirrhosis, a non-neoplastic
liver disease which may evolve in hepatocellular carci-
noma (19). In this latter case the pattern of serum levels
of this enzyme may be useful as an additional biochemi-
cal marker to identify cirrhotic patients at risk to develop
hepatocellular carcinoma. This finding may have clinical
relevance as, to date, no serum marker including a-foe-
toprotein has been found specifically reliable for the
early detection of precancerous lesions (20, 21). On the
basis of these considerations we have assessed cathep-
sin D serum mass concentrations in groups of patients
with hepatocellular carcinoma and/or liver cirrhosis and
evaluated its potential clinical interest in non-malignant
and malignant liver diseases.
Materials and Methods
Patients
This study was undertaken on a total of 159 patients with malignant
and non-malignant liver diseases whose clinical features are re-
ported in table 1. Ninety-eight registered healthy blood donors of
both sex were used as control. Diagnosis of hepatocellular carci-
noma was established by ultrasonography and by histological find-
ings following ultrasound-assisted fine-needle biopsy, evidence
from positive diagnostic imaging and clinical and biochemical
findings as well. Liver cirrhosis was diagnosed by histological
findings and on the basis of unequivocal clinical and biochemical
data. The Child-Pitgh classification (22) was used to evaluate the
grade of severity of cirrhosis. Liver steatosis was diagnosed by
histological findings. All subjects with steatosis had a positive se-
rum test for hepatitis C virus. Immunoenzymatic and biochemical
assays were performed on sera, previously stored at -80 °C, ob-
tained from venous blood samples of patients and healthy blood
donors.
Determination of cathepsin D serum mass
concentrations
Cathepsin D concentrations were determined by a commercially
available antibody-based immunoenzymatic kit (Ciba Corning
Diagnostics, Alarneda, USA) in sera of both healthy subjects and
patients and diluted 1 : 50 with the appropriate sample diluent in-
cluded in the kit. The assay detected both precursors (procathepsin
D, Mr 52 000, MT 48 000) and mature (Mr 34 000) forms of cathep-
sin D. The standard curve was linear from 0 up to 2.0 nmol/1. The
minimum detectable concentration, according to the manufacturer,
is 0.012 nmol/1. Mean cathepsin D serum mass concentrations in
normal subjects, + 2-fold the standard deviation value or the high-
est serum value of the enzyme determined in healthy subjects, were
taken as cut-off limits.
Determination of serum α-foetoprotpin and other
biochemical tests
α-Foetoprotein, the most sensitive and reliable serum marker for
the diagnosis of hepatocellular carcinoma (23), was determined in
healthy subjects and in patients by a commercially available immu-
noluminometric based assay kit (Byk Sangtec, Milan, Italy). Nor-
mal range values, according to the manufacturer, were 0-8 kIU/1.
Additionally, serum levels of 200 and 400 kIU/1 were used as cut-
off values as these concentrations have been reported to be highly
diagnostic for this tumour (20, 23, 24). Furthermore, the following
serum biochemical constituents were also assayed and their corre-
lation with cathepsin D was assessed: alkaline phosphatase1), albu-
min, alanine aminotransferase1), aspartate aminotfansferase1), bili-
rubin, γ-glutamyl-transferase1), prothrornbin. These assays were
done with commercially available standard kits.
Statistical analysis
Data analysis was computed by the Mann-Whitney and the
Kruskall-Wallis non-parametric tests. Linear regression analysis
was used to compute the relationship between cathepsin D and a-
foetoprotein serum concentrations in cancer patients and patients
with cirrhosis. Due to the uneven distribution of the data, the
Spearman rank correlation test was used to assess the correlation
between cathepsin D serum levels and Child-Pugh grade of sever-
ity of cirrhosis as well as between cathepsin D and the other bio-
chemical properties examined. P values < 0.05 were taken as sig-
nificant.
Results
Cathepsin D serum mass concentrations
Table 2 reports the mean ± standard error, the median
and the range of total serum cathepsin D content in all



















































Patients with positive serum test for hepatitis C virus. b Patients with positive serum test for hepatitis B virus.
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Tab. 2 Cathepsin D serum mass concentrations (nmol/1) in normal subjects and patients with



































Data analysis was computed by the Mann-Whiiney and Kniskall-
Wallis non-parametric test.
a P < 0.001 as compared to normal subjects;
b P < 0.04 as compared to benign steatosis;
c P < 0.006 as compared to hepatocellular carcinoma.
the examined groups. No significant difference in the
serum mass concentrations of this enzyme was observed
between female and male normal subjects (tab. 2). Sig-
nificantly higher cathepsin D serum mass concentrations
(mean 4—6 fold) were determined either in cancer or
cirrhotic patients as compared to normal subjects
(P < 0.001). Interestingly, cathepsin D serum mass con-
centrations in cirrhotic patients were significantly higher
(mean + 62%) than those measured in cancer patients
(P = 0.006) (tab. 2). Statistically significant increased
cathepsin D serum mass concentrations were also ob-
served in subjects with steatosis as compared to normal
subjects (P < O.O 1). However, these concentrations
were, in turn, significantly lower (mean 2—3 fold) than
those determined in the serum of cancer patients
(P < 0.04) or patients from cirrhosis (P < 0.001) (tab.
2). No significant correlation between cathepsin D se-
rum mass concentrations and tumour size (r — 0.23;
P = 0.23) or number of neoplastic lesions (r = 0.19;
P = 0.23) was evidenced in those patients evaluatable
for these properties (tab. 3). Furthermore, no correlation
between cathepsin D serum mass concentrations and
grade of severity of cirrhosis was further evidenced
(r = -0.78; P = 0.48) (tab. 3).
α-Foetoprotein serum concentrations
α-Foetoprotein serum concentrations were markedly ele-
vated (mean 842 fold) in cancer patients as compared to
normal subjects or patients with cirrhosis (P < 0.001)
(tab. 4). These concentrations were also significantly
increased (mean 6 fold) in patients with cirrhosis as
compared to normal subjects (P < 0.01). However, this
phenomenon occurred at a very lessened extent as com-
pared to cancer patients (tab. 4). The serum concentra-
tions of this protein were significantly different in pa-
tients with tumour size larger or smaller than 3 cm
(P < 0.05) and also significantly different in patients
with single or multiple neoplastic lesions (P < 0.02).
Furthermore, this tumour marker was significantly
correlated with tumour size (r = 0.49, P = 0.004) and
the number of malignant lesions (r = 0.47, P = 0.004)
(tab. 4). Finally, a significant correlation (r = 0.112,
P = 0.004), was evidenced between α-foetoprotein se-
rum levels and grade of severity of cirrhosis (tab. 4).
Correlation between cathepsin D and
biochemical properties of hepatocellular
carcinoma and cirrhosis
No relationship between cathepsin D and a-foetoprotein
levels was observed either in hepatocellular carcinoma
(r = -0.027, P = 0.87) or cirrhotic patients (r = 0.19,
P = 0.065) (data not shown). No further correlation with
the other examined biochemical properties of cholestasis
or cytolysis was evidenced (albumin: r = 0.13; alanine
aminotransferase: r = -0.3; aspartate aminotransferase:
r = —0.2; alkaline phosphatase: r = 0.27; bilirubin:
r = 0.03; γ-glutamyl-transferase: r = 0.28: prothrombin:
r = 0.103). P values were not significant in any of the
cases (data not shown).
Rate of increased cathepsin D and
α-foetoprotein in pat ients with hepatocel lular
carcinoma or cirrhosis
Cathepsin D serum mass concentrations higher than the
cut-off level of 24 nmol/1 (mean serum content in nor-
mal subjects + 2 standard deviations) were measured in
64.7% of cancer patients and in 88.0% of patients with
cirrhosis (tab. 5). At a cut-off level of 50 nmol/1 (highest
serum mass concentration measured in healthy subjects)
this phenomenon was observed in 37.2% of cancer pa-
tients and in 61.9% of patients with cirrhosis (tab. 5).
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Tab, 3 Cathepsin D scrum mass
and/or liver cirrhosis: distribution
Groups
Hepatocellular carcinoma
Tumour size <3 cm
Tumour size >3 cm







concentrations (nmol/l) in patients















50.3 48.3 ± 7.5
(3.2-123.3)
• I
43.2 44.7 ± 8.4
(6.4-123.3)
42.2 43.5 ± 6.2
(3.2-111.4)
60.4 66.8 ± 5.7
(10.3-196)
68.9 67.6 ± 7.0
(9.7-139.0)
58.6 59.7 ± 9.1
(8.7-145.5)
a Due to some missing samples, number of patients may be vari-
able.
Data analysis was computed by Mann-Whitney, Kruskall-Wallis and
Spearman rank correlation non-parametric tests. No significant dif-
ference or correlation between or among groups was evidenced.
Tab. 4 α-Foetoprotein serum concentrations (kIU/1) in normal subjects and patients with hepatocellular
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Tumour size >3 cm




















































a Variability in the number of patients is due to some missing sam-
ples.
Data analysis was computed by Mann-Wliitney, Kruskall-Wallis and
Spearman rank correlation non-parametric tests.
a P < 0.001 as compared to normal subjects and liver cirrhosis;
b P < 0.05 as compared to tumour size <3 cm;
c r = 0.49, Ρ < 0.004;
d Ρ < 0.05 as compared to unifocal;
e r = 0.47, Ρ < 0.004;
f Ρ < 0.01 as compared to normal subjects;
8 r = 0.112, Ρ = 0.004.
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Tab. 5 Rate of increased cathepsin D and α-foetoprotein serum































a Due to some missing samples, number of evaluable subjects in
this group is variable.
b Mean serum levels ± 2 SD in normal subjects.
c Highest cathepsin D serum values determined in normal subjects.
d Upper normal serum level according to the manufacturer's in-
structions.
c Cut-off levels which have been reported to be diagnostic for hep-
atocellular carcinoma (20, 23, 24).
Only 4/16 (25%) or 1/16 (6.2%) of subjects with
steatosis had a cathepsin D serum mass concentration
higher than 24 or 50 runol/1 respectively (data not
shown). Further, α-foetoprotein serum levels higher
than 8 kIU/1 (normal upper limit) were observed in
69.4% of patients with hepatocellular carcinoma and
in 34.8% of patients with cirrhosis (tab. 5). When 200
or 400 kIU/1 were selected as cut off values, 32.6%
and 24.5% of these patients showed increased levels
of this protein while, at a 200 kIU/1 cut-off limit, this
phenomenon occurred only in 2.2% of patients with
cirrhosis (tab. 5).
Discussion
Total cathepsin D serum mass concentrations (i. e. pro-
enzyme + mature form) were observed to be signifi-
cantly increased in patients with hepatocellular carci-
noma and/or liver cirrhosis as compared to normal sub-
jects. Interestingly, in cirrhotic patients these concentra-
tions were significantly higher (mean + 62%) than those
measured in cancer patients. Increased levels of this pro-
teinase were also observed in subjects with benign
steatosis, however these values were markedly (2—3
fold) lower than those measured in cancer patients and
patients with cirrhosis. These data further confirm, in
part, and extend some previous observations ofBrouillet
et al. (15) and Zuhlsdorftf. al. (25) who found evidence
of elevated mass concentrations of cathepsin D in the
plasma or sera of patients with various liver diseases
including hepatocellular carcinoma and cirrhosis. The
increased serum content of cathepsin D observed in both
cirrhotic and cancer patients may not only be the conse-
quence of cytolytic processes which occur during the
evolution of these pathological events but also related to
an active secretion of this enzyme by intact hepatocytes,
which contain most of the enzyme present in the human
liver tissue (26). This hypothesis, supported by previous
observations of Ryvnyak et al. (18) who showed that,
in rats with tetrahydrocarbon chloride-induced cirrhosis,
cathepsin D was largely secreted by intact heptocytes
and other connective tissue cells into the intercellular
space during cirrhosis, is further suggested by the pre-
sent data which showed the lack of a significant correla-
tion between cathepsin D serum mass concentrations
and some biochemical markers of cytolysis. As an al-
tered secretion of this enzyme has been reported to be
associated, at least in vitro, with some stages of onco-
genic transformation in rat fibroblasts and with differen-
tiation stages of some carcinoma cell lines (4, 27), it
would be conceivable to hypothesize that the increased
serum levels of this proteinase in cirrhotic patients may
also be associated with carcinogenetic processes which
may occur during the evolution of this disease. More-
over, a number of experimental in vitro and in vivo in-
vestigations have shown that cathepsin D may induce
tumour cell proliferation by acting as an autocrine mito-
gen (2, 5, 6) and that intraperitoneal injections of puri-
fied preparations of cathepsin D may stimulate DNA
synthesis and mitosis in intact mouse liver (28, 29). In
addition, other studies have suggested that cathepsin D
may be implicated in liver regeneration, remodelling and
resorption of fibrous tissues in cirrhosis (18, 29, 30) as
well as in the activation of latent precursor forms of
other proteolytic enzymes, such as cathepsin B and L,
involved in the degradation of collagen in fibrotic liver
and in tumour invasion and metastasis (31, 32). There-
fore, these findings lead further to the hyopthesis that
cathepsin D might be able to promote the malignant
transformation of cirrhotic tissue. These observations
may fit well with the higher cathepsin D serum mass
concentrations observed in cirrhotic patients as com-
pared to cancer patients. In conclusion, although these
results indicate that cathepsin D does not seem to be
more reliable than α-foetoprotein as a tool for the diag-
nosis of hepatocellular carcinoma, the increased serum
levels of this enzyme, in addition to other proposed po-
tential prognostic factors (33, 34), may be of interest as
an additional biochemical marker to identify patients
with cirrhosis who may develop precancerous nodules.
Prospective clinical investigations to better assess this
hypothesis are currently in progress.
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